The effectiveness and safety of octocog alfa in patients with hemophilia A: up to 7-year follow-up of the real-world AHEAD international study.

ABSTRACT:

Background

Real-world data assessing treatment outcomes in patients with hemophilia A in routine clinical practice are limited.

Objective

To evaluate the effectiveness and safety of octocog alfa in patients with moderate/severe hemophilia A receiving treatment in clinical practice.

Design

The international Antihemophilic Factor Hemophilia A Outcome Database study is an observational, noninterventional, prospective, multicenter study.

Methods

This planned interim data read-out was conducted following 7 years of observation of patients receiving octocog alfa (cut-off, 30 June 2020). The primary endpoint was joint health status, assessed by the Gilbert Score. Secondary endpoints included annualized bleeding rates (ABRs), Hemophilia Joint Health Score (HJHS), healt

SUBMITTER: Ozelo MC 

PROVIDER: S-EPMC10874143 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature